Floatz logo

17 assets in Breast Carcinoma In Situ

Therapeutic assets addressing Breast Carcinoma In Situ, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Exemestane
Breast Carcinoma In Situ
Alliance for Clinical Trials in OncologyP4BBB (72)
Letrozole
Breast Carcinoma In Situ
Alliance for Clinical Trials in OncologyP4BBB (72)
Tamoxifen
Breast Carcinoma In Situ
Alliance for Clinical Trials in OncologyP4BB (70)
Anastrozole
Breast Carcinoma In Situ
Alliance for Clinical Trials in OncologyP4BB (69)
Cyclophosphamide
Breast Carcinoma In Situ
Roswell Park Cancer InstituteP3BB (65)
Revaree Plus
Breast Carcinoma In Situ
Memorial Sloan Kettering Cancer CenterP4BB (65)
Cimetidine
Breast Carcinoma In Situ
Ohio State University Comprehensive Cancer CenterP2/3B (61)
Dexasone
Breast Carcinoma In Situ
Ohio State University Comprehensive Cancer CenterP2/3B (61)
Famotidine
Breast Carcinoma In Situ
Ohio State University Comprehensive Cancer CenterP2/3B (61)
Pembrolizumab
Breast Carcinoma In Situ
National Cancer Institute (NCI)P3B (60)
Diphenhydramine
Breast Carcinoma In Situ
Ohio State University Comprehensive Cancer CenterP2/3B (58)
Ranitidine
Breast Carcinoma In Situ
Ohio State University Comprehensive Cancer CenterP2/3B (58)
Anhydrous Enol-Oxaloacetate
Breast Carcinoma In Situ
Jonsson Comprehensive Cancer CenterP2B (57)
Brc-001
Breast Carcinoma In Situ
City of Hope Medical CenterP2CCC (53)
Starch
Breast Carcinoma In Situ
University of Michigan Rogel Cancer CenterP2CCC (53)
Trastuzumab
Breast Carcinoma In Situ
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityP2CCC (53)
(Z)-Endoxifen
Breast Carcinoma In Situ
National Cancer Institute (NCI)P1CC (43)